Dr. Cetnar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-6346Fax+1 608-266-6020
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2006 - 2009
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2002 - 2005
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
OR State Medical License 2013 - 2025
WI State Medical License 2009 - 2013
PA State Medical License 2006 - 2010
MN State Medical License 2005 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 84 citationsPhase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly
Lung Cancer. 2020-01-01 - 84 citationsTranscriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J. Alumkal, Duanchen Sun, Eric Lu, Tomasz M. Beer, George Thomas
Proceedings of the National Academy of Sciences of the United States of America. 2020-06-02 - 113 citationsEfficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.Fiona H Blackhall, Kevin Jao, Laurent Greillier, Byoung Chul Cho, Konstantin Penkov
Journal of Thoracic Oncology. 2021-02-16
Press Mentions
Stronger Rules Needed for Oncology Financial Conflicts of Interest, Critics ArgueMay 2nd, 2024- Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
